Alltrna was founded in 2018 by Flagship Pioneering, and is currently focused on targeting Stop Codon Disease, a collection of rare and more common disorders stemming from so-called nonsense mutations.

The firm’s platform is designed to optimize tRNA nucleotide sequences to create programmable medicines.

In August 2023, it raised $109 million in a series B round led by its founder and a number of top-tier investors.